ArticleBritish journal of cancer2018

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.

Erta Kalanxhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.